

Deepak L. Bhatt, M.D., M.P.H.

VA Boston Healthcare System
Boston, MA
dlbhattmd@post.harvard.edu

Robert A. Harrington, M.D.

Stanford University Medical School
Stanford, CA

for the CHAMPION PHOENIX Executive
Committee and Investigators

Since publication of their article, the authors report no further potential conflict of interest.

1. Steinhubl SR, Berger PB, Mann JT III, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. *JAMA* 2002; 288:2411-20. [Erratum, *JAMA* 2003;289:987.]
2. Widimsky P, Motovská Z, Simek S, et al. Clopidogrel pretreatment in stable angina: for all patients >6 h before elective coronary angiography or only for angiographically selected patients a few minutes before PCI? A randomized multicentre trial PRAGUE-8. *Eur Heart J* 2008;29:1495-503.
3. Leonardi S, Truffa AA, Neely ML, et al. A novel approach to systematically implement the universal definition of myocardial infarction: insights from the CHAMPION PLATFORM trial. *Heart* 2013 February 23 (Epub ahead of print).
4. White HD, Chew DP, Dauerman HL, et al. Reduced immediate ischemic events with cangrelor in PCI: a pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction. *Am Heart J* 2012;163(2):182.e4-190.e4.

DOI: 10.1056/NEJMc1305978

Correspondence Copyright © 2013 Massachusetts Medical Society.

INSTRUCTIONS FOR LETTERS TO THE EDITOR

Letters to the Editor are considered for publication, subject to editing and abridgment, provided they do not contain material that has been submitted or published elsewhere. Please note the following:

- Letters in reference to a *Journal* article must not exceed 175 words (excluding references) and must be received within 3 weeks after publication of the article.
- Letters not related to a *Journal* article must not exceed 400 words.
- A letter can have no more than five references and one figure or table.
- A letter can be signed by no more than three authors.
- Financial associations or other possible conflicts of interest must be disclosed. Disclosures will be published with the letters. (For authors of *Journal* articles who are responding to letters, we will only publish new relevant relationships that have developed since publication of the article.)
- Include your full mailing address, telephone number, fax number, and e-mail address with your letter.
- All letters must be submitted at authors.NEJM.org.

Letters that do not adhere to these instructions will not be considered. We will notify you when we have made a decision about possible publication. Letters regarding a recent *Journal* article may be shared with the authors of that article. We are unable to provide prepublication proofs. Submission of a letter constitutes permission for the Massachusetts Medical Society, its licensees, and its assignees to use it in the *Journal*'s various print and electronic publications and in collections, revisions, and any other form or medium.

CORRECTIONS

Selection Criteria for Lung-Cancer Screening (February 21, 2013; 368:728-36). Five instances of the study name PLCO_{M2012} should have been PLCO_{M2011}: two in the first paragraph of the Statistical Analysis subsection of Methods (page 729), one in the first paragraph of the Modified PLCO Lung-Cancer Risk-Prediction Model (PLCO_{M2012}) subsection of Results (page 732), and one each in the first and second paragraphs of the Discussion (pages 733 and 734). The article is correct at NEJM.org.

Brief Report: Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia (November 8, 2012;367:1814-20). Near the bottom of the phylogenetic tree in Figure 2B (page 1818), the bovine coronavirus listed as HCoV-HVU1 should have been HCoV-HKU1. The article is correct at NEJM.org.

NOTICES

Notices submitted for publication should contain a mailing address and telephone number of a contact person or department. We regret that we are unable to publish all notices received. Notices also appear on the Journal's website (NEJM.org/medical-conference). The listings can be viewed in their entirety or filtered by specialty, location, or month.

A COMPREHENSIVE BOARD REVIEW IN HEMATOLOGY AND MEDICAL ONCOLOGY 2013

The course will be offered in Houston, Sept. 23–28. It is jointly presented by the University of Texas MD Anderson Cancer Center and Baylor College of Medicine.

Contact the University of Texas MD Anderson Cancer Center, Department of CME/Conference Management, Unit 1381, P.O. Box 301439, Houston, TX 77230-1439; or call (713) 792-2223 or (866) 531-MOBR (6627); or e-mail register@mdanderson.org; or see <http://www.mdanderson.org/hmobr>.

1ST ZEBRAFISH FOR PERSONALIZED/PRECISION MEDICINE CONFERENCE

The conference will be held in Toronto, Oct. 16–18. It is presented by the Zebrafish Center for Advanced Drug Discovery, St. Michael's Hospital.

Contact Alia Bye, St. Michael's Hospital, 193 Yonge St., Toronto, ON M5B 1M8, Canada; or call (416) 864-6060, extension 7844; or e-mail zconference@smh.ca; or see <https://www.zebrafishcentre.com/conference>.

AMERICAN SOCIETY OF TROPICAL MEDICINE AND HYGIENE

The following meetings will be held: "Intensive Update Course in Clinical Tropical Medicine and Travelers' Health" (San Francisco, Sept. 30 and Oct. 1) and "ASTMH 62nd Annual Meeting" (Washington, DC, Nov. 13–17).

Contact the American Society of Tropical Medicine and Hygiene, 111 Deer Lake Rd., Suite 100, Deerfield, IL 60015; or call (847) 480-9592; or fax (847) 480-9282; or see <http://www.astmh.org>.

THE JOURNAL'S WEB AND E-MAIL ADDRESSES:

For letters to the Editor: authors.NEJM.org
For information about the status of a submitted manuscript:
authors.NEJM.org
To submit a meeting notice: meetingnotices@NEJM.org
The *Journal*'s web pages: NEJM.org